How to improve R&D productivity¶
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9(3), 203-214.
Cited by¶
2 citations across 2 artifacts.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Anna Karenina Principle
- In drug development, a molecule must pass potency, selectivity, safety, manufacturability, pharmacokinetics, market need, and regulatory approval; the attrition curve is the pattern made quantitative.
This sourceDocuments the staged-attrition drug pipeline and the low survival rate of small-molecule candidates from discovery to approval as the conjunctive-necessity pattern made quantitative.
Supported in partVerified against the publisher's abstract
The source's abstract documents a staged, industry-wide analysis of attrition across drug discovery and development; it does not enumerate the seven properties or the 'attrition curve' the claim asserts.
“Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity.”
- In drug development, a molecule must pass potency, selectivity, safety, manufacturability, pharmacokinetics, market need, and regulatory approval; the attrition curve is the pattern made quantitative.
Domain-specific¶
- Riskiest Assumption Test
- Lean-startup product development — the named home: design the cheapest experiment (a presales page, a concierge test) that could falsify the riskiest product assumption before scaling, and pivot if it fails. Pharmaceutical R&D ("killer experiment" / kill-fast pipeline) — early, cheap, hard-to-pass tests on the single assumption most likely to fail (efficacy in the predictive model, toxicity profile), run precisely to avoid the far larger downstream cost of a Phase III failure.
This sourceThe 'quick win, fast fail' R&D paradigm, which focuses investment on early clinical development (target selection to clinical proof-of-concept) to reduce late-stage Phase II/III attrition.
Supported in partVerified against the work's full text
“Reducing late-stage (Phase II and III) attrition rates and cycle times during drug development are among the key requirements for improving R&D productivity.”
- Lean-startup product development — the named home: design the cheapest experiment (a presales page, a concierge test) that could falsify the riskiest product assumption before scaling, and pivot if it fails. Pharmaceutical R&D ("killer experiment" / kill-fast pipeline) — early, cheap, hard-to-pass tests on the single assumption most likely to fail (efficacy in the predictive model, toxicity profile), run precisely to avoid the far larger downstream cost of a Phase III failure.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 2 of 2 citations: 2 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:7dfa4d24e320 · see in the full table